Hidden heart risk in obesity: can early screening save lives?
NCT ID NCT06137261
First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time
Summary
This trial tests whether actively screening adults with obesity for early signs of heart failure can improve their health outcomes. Adults aged 45 and older with a BMI of 30 or higher, who have no known heart disease, will be randomly assigned to receive either standard care or an extra screening that includes a physical exam, ECG, blood tests, and an echocardiogram. The goal is to see if this screening uncovers hidden heart problems and leads to earlier treatment, potentially preventing serious heart failure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Active screening for heart failure using medical history, physical exam, ECG, blood tests, and echocardiogram
- What this could lead to
- If screening catches hidden heart problems early, it could lead to earlier treatment and better heart health for people with obesity.
- What could go wrong
- This is a single trial, and screening may find issues that would not have caused problems, leading to extra tests or worry. The benefit is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 420 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥45 year * BMI ≥30 kg/m2 * Written informed consent. Exclusion Criteria: * Known cardiac disease (determined by asking the patient and by assessment of the available patient files). * Treatment with weight-reducing medication.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Franciscus Gasthuis & Vlietland
Rotterdam, 3045 PM, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The acute effects of an endurance exercise bout the gut microbiome and gut-derived metabolome in Women's distinct fitness and body mass indexes
- Pilot study to evaluate the effect of nicotinamide riboside on immune activation in psoriasis
- The feasibility of electrical impedance tomography to guide non-invasive respiratory interventions in chronic respiratory disease
- The impact of video-based cardiac rehabilitation education in patients with cardiovascular implantable electronic Devices(CIEDs)- a randomized controlled trial
- Effect of the use of dapagliflozin in diuresis, natriuresis and in ultrafiltration and peritoneal elimination of sodium, in patients with refractory heart failure
- Can a new injection help tackle obesity? a trial puts it to the test